SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Pharmova informs about change in directorate

26 Mar 2024 Evaluate
Pursuant to Regulation 30 of the SEBI Listing Regulations, Jubilant Pharmova has informed that based on the recommendations of the Nomination, Remuneration & Compensation Committee, the Board of Directors of the Company at its meeting held on March 26, 2024 at 11:00 AM (IST) and concluded at 11:40 AM (IST), appointed Dr. Harsh Mahajan (DIN: 00824227) and Shivpriya Nanda (DIN: 01313356), as an Additional Director (Non-Executive, Independent) on the Board of the Company with effective from April 1, 2024 for an initial term of five (5) years i.e., up to March 31, 2029, subject to approval of the shareholders to be obtained within three (3) months hereof. Further, Srinivasan Sridhar (DIN: 00004272), Sudha Pillai (DIN: 02263950) and Dr. Ashok Misra (DIN: 00006051), Independent Directors of the Company shall complete their second term on March 31, 2024 and accordingly cease to be an Independent Director on Board of the Company with effect from the closing hours of March 31, 2024. The composition of the Board of Directors of the Company is in compliance with the requirements prescribed under the Companies Act, 2013 and SEBI Listing Regulations. The disclosure required under Regulation 30 of the SEBI (LODR) Regulations, 2015 are enclosed as Annexure-I and Annexure-II. This information will also be available on the website of the Company at www.jubilantpharmova.com.

The above information is a part of company’s filings submitted to BSE.

Jubilant Pharmova Share Price

911.60 6.55 (0.72%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×